This website uses cookies primarily for visitor analytics. Certain pages will ask you to fill in contact details to receive additional information. On these pages you have the option of having the site log your details for future visits. Indicating you want the site to remember your details will place a cookie on your device. To view our full cookie policy, please click here. You can also view it at any time by going to our Contact Us page.

Artificial spleen could be used to treat bloodstream infections

31 March 2013

The Wyss Institute at Harvard has been awarded funds to develop an innovative artificial spleen that could save soldiers' lives in combat situations.

The spleen-on-a-chip, developed at the Wyss Institute, Harvard: (photo: Wyss Institute)

The Wyss Institute for Biologically Inspired Engineering at Harvard University has been awarded a $9.25m contract from the US Defense Advanced Research Projects Agency (DARPA) to further advance a blood-cleansing technology developed at the Institute with prior DARPA support, and help accelerate its translation to humans as a new type of sepsis therapy.

The device will be used to treat bloodstream infections that are the leading cause of death in critically ill patients and soldiers injured in combat.
 
To rapidly cleanse the blood of pathogens, the patient's blood is mixed with magnetic nanobeads coated with a genetically engineered version of a human blood 'opsonin' protein that binds to a wide variety of bacteria, fungi, viruses, parasites, and toxins.

It is then flowed through microchannels in the device where magnetic forces pull out the bead-bound pathogens without removing human blood cells, proteins, fluids, or electrolytes - much like a human spleen does. The cleansed blood then flows back to the patient.
 
"In just a few years we have been able to develop a suite of new technologies, and to integrate them to create a powerful new device that could potentially transform the way we treat sepsis," says Wyss founding director and project leader, Don Ingber.

"The continued support from DARPA enables us to advance our device manufacturing capabilities and to obtain validation in large animal models, which is precisely what is required to enable this technology to be moved towards testing in humans."
 
The team will work to develop manufacturing and integration strategies for its core pathogen-binding opsonin and Spleen-on-a-Chip fluidic separation technologies, as well as a novel coating technology called "SLIPS," which is a super-hydrophobic coating inspired from the slippery surface of a pitcher plant that repels nearly any material it contacts.

By coating the inner surface of the channels of the device with SLIPS, blood cleansing can be carried out without the need for anticoagulants to prevent blood clotting.
 


Print this page | E-mail this page

Igus - Tech Up, Costs Down